SpringWorks Therapeutics (NasdaqGS:SWTX) - Share price, News & Analysis

SWTX fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

SWTX Stock Overview

SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer.

Rewards

Revenue is forecast to grow 64.29% per year

Risk Analysis

Makes less than USD$1m in revenue ($0)

Currently unprofitable and not forecast to become profitable over the next 3 years

Volatile share price over the past 3 months

SpringWorks Therapeutics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for SpringWorks Therapeutics
Historical stock prices
Current Share Price	US$38.00
52 Week High	US$89.75
52 Week Low	US$33.33
Beta	1
1 Month Change	-19.71%
3 Month Change	-31.99%
1 Year Change	-51.01%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	67.92%

Recent News & Updates

May 02

SpringWorks Therapeutics: Rating Buy Ahead Of Mid-Year Data Releases

Data from Phase 3 trial for Nirogacestat in treating desmoid tumors and Phase 2 combination trial with anti-BCMA antibody Blenrep in relapsed/refractory multiple myeloma is expected in mid-year. The company has multiple partnerships (including with Pfizer, GlaxoSmithKline, Janssen, Seattle Biosciences, Allogene, etc.) to combine Nirogacestat with their anti-BCMA therapies. The stock could have a 50% return potential after the data from the above trials.

Dec 30

Companies Like SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Dec 14

SpringWorks Is A Biotech To Watch With Several Partnerships And Solid Drug Pipeline

Results from the phase 3 DeFi study using Nirogacestat as a monotherapy for patients with desmoid tumors are expected to be released end of 2021 or early 2022. Nirogacestat is being explored in 7 combinations trials for the treatment of patients with multiple myeloma. The global multiple myeloma market is expected to reach $19.8 billion by 2027. Most recent partnership for SpringWorks' Nirogacestat was with AbbVie, and it becomes 7th one targeting patients with multiple myeloma.

Shareholder Returns

	SWTX	US Biotechs	US Market
7D	1.5%	0.7%	-0.5%
1Y	-51.0%	-21.4%	-12.3%

Return vs Industry: SWTX underperformed the US Biotechs industry which returned -21.7% over the past year.

Return vs Market: SWTX underperformed the US Market which returned -12.9% over the past year.

Price Volatility

Is SWTX's price volatile compared to industry and market?
SWTX volatility
SWTX Average Weekly Movement	12.6%
Biotechs Industry Average Movement	12.3%
Market Average Movement	7.8%
10% most volatile stocks in US Market	16.9%
10% least volatile stocks in US Market	2.9%

Stable Share Price: SWTX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: SWTX's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2017	190	Saqib Islam	https://www.springworkstx.com

SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors.

SpringWorks Therapeutics Fundamentals Summary

How do SpringWorks Therapeutics's earnings and revenue compare to its market cap?
SWTX fundamental statistics
Market Cap	US$1.86b
Earnings (TTM)	-US$205.92m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-9.0x

P/E Ratio

Is SWTX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
SWTX income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$205.92m
Earnings	-US$205.92m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-4.21
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did SWTX perform over the long term?

See historical performance and comparison

Valuation

Is SpringWorks Therapeutics undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

4.94x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate SWTX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate SWTX's fair value for valuation analysis.

Price To Earnings Ratio

PE vs Industry: SWTX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: SWTX is unprofitable, so we can't compare its PE Ratio to the US market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SWTX's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: SWTX is overvalued based on its PB Ratio (4.9x) compared to the US Biotechs industry average (1.5x).

Future Growth

How is SpringWorks Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

55.9%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SWTX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SWTX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SWTX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SWTX's revenue (64.3% per year) is forecast to grow faster than the US market (7.8% per year).

High Growth Revenue: SWTX's revenue (64.3% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: SWTX is forecast to be unprofitable in 3 years.

Past Performance

How has SpringWorks Therapeutics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-54.9%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: SWTX is currently unprofitable.

Growing Profit Margin: SWTX is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: SWTX is unprofitable, and losses have increased over the past 5 years at a rate of 54.9% per year.

Accelerating Growth: Unable to compare SWTX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SWTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).

Return on Equity

High ROE: SWTX has a negative Return on Equity (-54.65%), as it is currently unprofitable.

Financial Health

How is SpringWorks Therapeutics's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: SWTX's short term assets ($356.0M) exceed its short term liabilities ($23.2M).

Long Term Liabilities: SWTX's short term assets ($356.0M) exceed its long term liabilities ($5.5M).

Debt to Equity History and Analysis

Debt Level: SWTX is debt free.

Reducing Debt: SWTX has not had any debt for past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SWTX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: SWTX has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 49.3% each year.

Dividend

What is SpringWorks Therapeutics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate SWTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SWTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SWTX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SWTX's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as SWTX has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.0yrs

Average management tenure

CEO

Saqib Islam (51 yo)

3.83yrs

Tenure

US$17,542,057

Compensation

Mr. Saqib Islam, J.D. serves as Chief Executive Officer and Director at SpringWorks Therapeutics, Inc. since August 2018. He serves as an Independent Director of Passage Bio, Inc. since March 2019. Mr. Isl...

CEO Compensation Analysis

Compensation vs Market: Saqib's total compensation ($USD17.54M) is above average for companies of similar size in the US market ($USD5.44M).

Compensation vs Earnings: Saqib's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: SWTX's management team is not considered experienced ( 2 years average tenure), which suggests a new team.

Board Members

Experienced Board: SWTX's board of directors are considered experienced (4.8 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/05/24 00:00
End of Day Share Price	2022/05/23 00:00
Earnings	2022/03/31
Annual Earnings	2021/12/31